Impact of the women's health initiative study [4]

British Journal of General Practice

Volumn 54, Issue 501, 2004, Pages 301-302

  Cogliano, Mimi ^a   Gebbie, Ailsa E ^b  

^a Crewe Medical Centre   (United Kingdom)

^b Family Planning and Well Woman Services   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE;

DRUG INDICATION; DRUG WITHDRAWAL; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; GENDER; GENERAL PRACTICE; GENERAL PRACTITIONER; HORMONE SUBSTITUTION; HUMAN; LETTER; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; SCORING SYSTEM; SEX DIFFERENCE; UNITED KINGDOM; VASOMOTOR DISORDER; VISUAL ANALOG SCALE;

ATTITUDE OF HEALTH PERSONNEL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; WOMEN'S HEALTH;

EID: 1842738235     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Wilson RA. Feminine Forever. New York: M Evans & Company Inc., 1968.
2. Rossouw JE, Anderson GL, Prentice RL, et al [Writing group for the Women's Health Initiative investigators]. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333.
3. Beral V, Million women study collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
4. Information and Statistics Division, NHS Scotland, Primary Care Information Group. HRT prescribing in Lothian NHS Health Board by drug name for August 2001-July 2002. Scotland: NHS Scotland, 2002.
5. Lagro-Janssen T, Rossner WW, van Weel C. Breast cancer and hormone-replacement therapy: Up to general practice to pick up the pieces. Lancet 2003; 362(9392): 414-415.